近期艾德生物（300685）发布2025年中报，证券之星财报模型分析如下： 营收与利润 艾德生物发布的2025年中报显示，截至报告期末，公司营业总收入为5.79亿元，同比上升6.69%。归母 净利润为1.89亿元，同比上升31.41%，扣非净利润为1.85亿元，同比上升39.97%。这表明公司在报告期 内实现了较为稳健的营收增长，且净利润显著提升。 按单季度数据看，第二季度营业总收入为3.07亿元，同比下降0.8%，但第二季度归母净利润为9856.56 万元，同比上升23.74%，扣非净利润为9757.26万元，同比上升30.03%。尽管第二季度营收略有下降， 但净利润仍保持较高增速。 每股净资产为4.82元，同比增加8.83%；每股经营性现金流为0.44元，同比增加24.78%；每股收益为0.48 元，同比增加33.33%。 主营业务构成 公司主营业务收入主要来自检测试剂、药物临床研究服务、检测服务及其他业务。其中，检测试剂收入 为4.83亿元，占主营收入的83.43%，毛利率高达90.72%；药物临床研究服务收入为5698.83万元，占 9.84%，毛利率为53.14%；检测服务收入为3250.49万元， ...

Group 1 - The core viewpoint of the news is that Aide Biological has shown a significant increase in stock price and performance metrics, despite being ranked lower in the industry PE ratio [1] - As of July 8, Aide Biological's closing stock price was 22.84 yuan, up 5.50%, with a rolling PE ratio of 31.81, marking a new low in 64 days and a total market capitalization of 8.943 billion yuan [1] - The company is ranked 68th in the medical device industry, which has an average PE ratio of 51.58 and a median of 37.46 [1] Group 2 - As of the first quarter of 2025, 27 institutions held shares in Aide Biological, including 20 funds, 6 other entities, and 1 social security fund, with a total holding of 197.0434 million shares valued at 4.414 billion yuan [1] - Aide Biological specializes in tumor gene testing reagents, software, and supporting instruments, as well as providing testing services and drug clinical research services [1] - The latest performance report for the first quarter of 2025 shows that the company achieved an operating income of 272 million yuan, a year-on-year increase of 16.63%, and a net profit of 90.4718 million yuan, a year-on-year increase of 40.92%, with a sales gross margin of 83.48% [1]

Company Overview - Xiamen Aide Biological Technology Co., Ltd. specializes in tumor gene testing reagents, software, and supporting instruments, as well as providing testing services and drug clinical research services [1] - The main products include testing reagents, testing services, and drug clinical research services [1] Financial Performance - For Q1 2025, the company reported revenue of 272 million yuan, a year-on-year increase of 16.63% [1] - The net profit for the same period was 90.47 million yuan, reflecting a year-on-year growth of 40.92% [1] - The sales gross margin stood at 83.48% [1] Market Position - As of July 2, the company's stock closed at 21.28 yuan, down 1.48%, with a rolling PE ratio of 29.64 times [1] - The total market capitalization is 8.332 billion yuan [1] - In comparison to the medical device industry, which has an average PE ratio of 51.29 times and a median of 37.02 times, Aide Biological ranks 67th [1][2] Capital Flow - On July 2, the net outflow of main funds for Aide Biological was 11.87 million yuan, with a total outflow of 19.57 million yuan over the past five days [1]